A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics after high Single Ascending Oral Doses of AZD1656 in T2DM Patients

Study identifier:D1020C00044

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after high Single Ascending Oral Supratherapeutic Doses of AZD1656 in Male Type 2 Diabetes Mellitus (T2DM) Patients

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD1656, Placebo

Sex

Male

Actual Enrollment

24

Study type

Interventional

Age

20 Years - 60 Years

Date

Study Start Date: 01 Oct 2010
Primary Completion Date: 01 Jan 2011
Study Completion Date: 01 Jan 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria